Sales of COVID-19 Antibody Test Reagent Kits
First written in FY2021-Q1. 4 of 7 entries say "Restated". Latest entry: FY2024-Q3.
The whole theme swung hardest in 2022: 5 of 8 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「In the biomedical business, overseas sales of stirring and defoaming equipment were strong, resulting in higher revenue,」
Compared with the previous situation, which included declining antibody test reagent kit sales, strong overseas sales of stirring and defoaming equipment resulted in higher revenue this time. - FY2022WorsenedAnnual report
「In the biomedical business, stirring and defoaming equipment performed well, but sales of novel coronavirus antibody test reagent kits declined.」
While sales of antibody test reagent kits continued to decline, stirring and defoaming equipment performed well. - FY2022-Q3RestatedAnnual report
「The biomedical business's mixing and degassing equipment performed well, but sales of the COVID-19 antibody test reagent kit declined.」
While sales of antibody test reagent kits continued to decline, stirring and defoaming equipment performed well. - FY2022-Q2RestatedAnnual report
「Sales of cell products and automated nucleic acid isolation systems and other biomedical-related products were solid, but sales of novel coronavirus antibody test reagent kits declined.」
Sales of cell products and automated nucleic acid isolation systems and other products were solid, while the decline in antibody test reagent kit sales continued. - FY2022-Q1WorsenedAnnual report
「Sales of cell products and automated nucleic acid isolation systems and other biomedical-related products were solid, but sales of novel coronavirus antibody test reagent kits declined.」
Sales of cell products and automated nucleic acid isolation systems and other products were solid, while sales of antibody test reagent kits declined. - FY2021-Q3RestatedAnnual report
「In the biomedical field, sales of novel coronavirus antibody test reagent kits, which began in March 2020, remained strong,」
The strong performance of antibody test reagent kits launched in March 2020 continued to be reported. - FY2021-Q1First statedAnnual report
「The biomedical field reported higher revenue as automated nucleic acid extraction systems performed solidly and the new coronavirus antibody test reagent kit, which began sales in March 2020, also performed well.」
Sales of novel coronavirus antibody test reagent kits, which began in March 2020, were described for the first time as a standalone theme, including their strong sales performance and contribution to higher revenue.